Our survey addressed testing rates by NSCLC histology, mutations with more recently approved targeted therapy (TRK, RET, MET), plus those with therapy under approval consideration (KRAS, HER2) at the time of survey conduction. This evidence concerns the gene MET and non-small cell lung carcinoma.